Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine
Countries: India Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 17 results found since Jan 2013.
Proceedings of the expert consensus group meeting on herpes zoster disease burden and prevention in India: An opinion paper
Hum Vaccin Immunother. 2023 Jun 9:2220608. doi: 10.1080/21645515.2023.2220608. Online ahead of print.ABSTRACTHerpes zoster (HZ) is a debilitating viral infection causing a dermatomal vesicular rash. Many known risk factors exist in India and adults >50 years of age may be especially susceptible to HZ. However, HZ is not a notifiable disease in India and data on incidence and disease burden is lacking. An Expert Consensus Group meeting was conducted with experts from relevant specialties to discuss HZ disease, its local epidemiology, and suggestions for implementing HZ vaccination in the Indian healthcare system. Current...
Source: Herpes - June 9, 2023 Category: Infectious Diseases Authors: V Ramasubramanian Agam Vora Youness Lagoubi Nicolas Lecrenier Yashpal Chugh Source Type: research
Cutaneous Adverse Drug Reactions (CADRs) to COVID19 Vaccines: A Case Series
Indian Dermatol Online J. 2023 Apr 27;14(3):383-387. doi: 10.4103/idoj.idoj_109_22. eCollection 2023 May-Jun.ABSTRACTViral vector vaccines (Covishield) and inactivated vaccines (Covaxin) are now being administered worldwide to reduce the impact of life-threatening corona virus disease 19 (COVID-19). Various cutaneous adverse drug reactions (CADRs) have been reported following COVID-19 vaccination. Here, we are reporting series of CADRs following COVID-19 vaccination. Among 18 CADRs, 4 each were of acute urticaria and pityriasis rosea, 2 each of leukocytoclastic vasculitis and herpes zoster, 3 exacerbation of psoriasis, and...
Source: Herpes - June 2, 2023 Category: Infectious Diseases Authors: Manila Purushottam Vinutha Rangappa Jayadev B Betkerur Ashwini P Kombettu Veeranna Shastry Source Type: research
Pole-to-pole involvement of varicella zoster virus reactivation following COVID-19 vaccination
We present a possible link between anti-SARS-CoV-2 virus vaccination and varicella zoster reactivation in these patients and also describe the clinical features, imaging findings including confocal imaging, corneal nerve fiber analysis, and management with detailed discussion.PMID:37203073 | DOI:10.4103/IJO.IJO_2942_22
Source: Herpes - May 19, 2023 Category: Infectious Diseases Authors: Padmamalini Mahendradas Yash Parmar Sai Bhakti Mishra Aditya Patil Ankush Kawali Srinivasan Sanjay Bhujang Shetty Source Type: research
Spectrum of Serious Neurological and Psychiatric Adverse Events in Indian COVID-19 Vaccine Recipients: A Systematic Review of Case Reports and Case Series
Neurol India. 2023 Mar-Apr;71(2):209-227. doi: 10.4103/0028-3886.375420.ABSTRACTIndian data regarding serious neurological and psychiatric adverse events, following coronavirus disease 2019 (COVID-19) vaccination, are lacking. We, therefore, systematically evaluated cases of post-vaccinal serious neurological and psychiatric adverse reactions published from India. A systematic review of cases published from India, which were archived in PubMed, Scopus, and Google Scholar databases, was performed; pre-print databases along with ahead-of-print contents were searched in addition. Retrieved articles, as on June 27, 2022, were ...
Source: Herpes - May 6, 2023 Category: Infectious Diseases Authors: Ravindra Kumar Garg Vimal Paliwal Hardeep Singh Malhotra Balendra Pratap Singh Imran Rizvi Neeraj Kumar Source Type: research
Spectrum of Mucocutaneous Reactions to COVID-19 Vaccination: A Report from a Web-Based Study from India
CONCLUSION: Majority reported mild and self-limiting reactions. This outcome should not discourage the common man in getting vaccinated.PMID:36092222 | PMC:PMC9455097 | DOI:10.4103/ijd.ijd_893_21
Source: Herpes - September 12, 2022 Category: Infectious Diseases Authors: Abheek Sil Deepak Jakhar Anupam Das Soumya Jagadeesan Sujala Sacchidanand Aradhya Source Type: research
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Acute herpes zoster radiculopathy mimicking cervical radiculopathy after ChAdOx1 nCoV-19/AZD1222 vaccination
This report aims to highlight the diagnostic dilemma between cervical radiculopathy secondary to spondylosis and zoster radiculopathy and how an erroneous diagnosis could result in inappropriate, aggressive surgical intervention and delayed treatment with antiviral therapy.PMID:35459652 | DOI:10.1136/bcr-2022-248943
Source: Herpes - April 23, 2022 Category: Infectious Diseases Authors: Andrew Dermawan Matthew Jun Min Ting Thomas Chemmanam Chok Lui Source Type: research
Disseminated and localised herpes zoster following Oxford-AstraZeneca COVID-19 vaccination
Indian J Dermatol Venereol Leprol. 2022 Mar 31:1-4. doi: 10.25259/IJDVL_819_2021. Online ahead of print.NO ABSTRACTPMID:35389012 | DOI:10.25259/IJDVL_819_2021
Source: Herpes - April 7, 2022 Category: Infectious Diseases Authors: Zi-Han Jiang Lai-San Wong Chih-Hung Lee Ting-Jung Hsu Yi-Hsiang Yu Source Type: research
Herpes zoster following vaccination with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant)
We report a case series of 7 patients who developed herpes zoster (HZ) following the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (recombinant). HZ following vaccination is a rare entity. The occurrence of HZ in the patients presented in this series within the time window 1-21 days after vaccination defined for increased risk and postulated dysregulation of T-cell-mediated immunity, suggests that the ChAdOx1 nCoV-19 coronavirus vaccine (recombinant) could probably be a trigger for reactivation of varicella zoster virus to cause HZ in them.PMID:35381724 | DOI:10.4103/ijph.ijph_2017_21
Source: Herpes - April 6, 2022 Category: Infectious Diseases Authors: Anupa Mary Job Bindurani Sudhamani Manju Mohan S N Mohanasundaram Source Type: research
